Literature DB >> 14646355

Amlodipine increases endothelial nitric oxide by dual mechanisms.

Reinhard Berkels1, Dirk Taubert, Henning Bartels, Thomas Breitenbach, Wolfgang Klaus, Renate Roesen.   

Abstract

Several experimental and clinical studies have demonstrated the antiatherogenic profile of the long-acting calcium antagonist amlodipine. Given the pivotal role of endothelial (dys)function during atherogenesis, we investigated the influence of amlodipine on endothelial nitric oxide (NO) bioavailability. Acute addition of amlodipine to segments of porcine coronary arteries resulted in a significant increase in NO release which could be blocked by the NO synthase inhibitor L-NMMA (N-monomethylarginine). This effect was mirrored by a rise in intracellular cGMP levels in porcine endothelial cell cultures. Long-term (24 h) treatment of porcine endothelial cell cultures with amlodipine (0.1-10 micromol/l) significantly enhanced the basal NO formation in a concentration-dependent manner which was abrogated in the presence of L-NMMA (0.1 mmol/l). In EA.hy 926 endothelial cells, amlodipine treatment for 24 h significantly increased the endothelial NO synthase protein expression. To evaluate whether the observed increase in NO was additionally due to an antioxidative protection of NO, we examined the influence of amlodipine in different in vitro models. In a cell-free system, amlodipine quenched superoxide anions (hypoxanthine/xanthine oxidase assay) at high concentrations (150 micromol/l). Addition of artificial membrane preparations (dimyristoylphosphatidylcholine) to mimic a physiological environment significantly enhanced this antioxidative effect. In a more physiological model of hyperglycemia (30 mmol/l, 20 min) induced formation of reactive oxygen species from native endothelial cells of porcine coronary arteries, amlodipine concentration dependently attenuated the reactive oxygen species release (>60%; 10 micromol/l). We conclude, that amlodipine increases the endothelial NO bioavailability, firstly via enhanced NO formation and secondly by prolonging the half-life of NO through antioxidative properties. This may result in an improved endothelial function. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14646355     DOI: 10.1159/000074241

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  14 in total

1.  Tolerability and effectiveness of (S)-amlodipine compared with racemic amlodipine in hypertension: a systematic review and meta-analysis.

Authors:  Fang Liu; Meng Qiu; Suo-Di Zhai
Journal:  Curr Ther Res Clin Exp       Date:  2010-02

2.  Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs.

Authors:  Kwang Kon Koh; Michael J Quon; Seung Hwan Han; Yonghee Lee; Soo Jin Kim; Yesl Koh; Eak Kyun Shin
Journal:  Int J Cardiol       Date:  2008-12-06       Impact factor: 4.164

3.  Management of a mixed overdose of calcium channel blockers, β-blockers and statins.

Authors:  Reena Thakrar; Rob Shulman; Geoff Bellingan; Mervyn Singer
Journal:  BMJ Case Rep       Date:  2014-06-06

Review 4.  Clinical roles of calcium channel blockers in ischemic heart diseases.

Authors:  Daisuke Sueta; Noriaki Tabata; Seiji Hokimoto
Journal:  Hypertens Res       Date:  2017-01-26       Impact factor: 3.872

5.  Effects of telmisartan or amlodipine monotherapy versus telmisartan/amlodipine combination therapy on vascular dysfunction and oxidative stress in diabetic rats.

Authors:  Hanke Mollnau; Matthias Oelze; Elena Zinßius; Michael Hausding; Zhixiong Wu; Maike Knorr; Jasmin Ghaemi Kerahrodi; Swenja Kröller-Schön; Thomas Jansen; Christine Teutsch; Carolyn Foster; Huige Li; Philip Wenzel; Eberhard Schulz; Thomas Münzel; Andreas Daiber
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-02-27       Impact factor: 3.000

6.  Methylene blue reverses recalcitrant shock in β-blocker and calcium channel blocker overdose.

Authors:  Nidhi Aggarwal; Yizhak Kupfer; Chanaka Seneviratne; Sidney Tessler
Journal:  BMJ Case Rep       Date:  2013-01-18

7.  Misinterpretation of the effect of amlodipine on cytosolic calcium concentration with fura-2 fluorospectrometry.

Authors:  Masayoshi Asai; Kazuhiko Takeuchi; Shinya Uchida; Tsuyoshi Urushida; Hideki Katoh; Hiroshi Satoh; Shizuo Yamada; Hideharu Hayashi; Hiroshi Watanabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-29       Impact factor: 3.000

8.  An Open Label Parallel Group Study to Assess the Effects of Amlodipine and Cilnidipine on Pulse Wave Velocity and Augmentation Pressures in Mild to Moderate Essential Hypertensive Patients.

Authors:  Rama Mohan Pathapati; Sujith Tumkur Rajashekar; Madhavulu Buchineni; Rajesh Kumar Meriga; Chirra Bhakthavasthala Reddy; Kolla Praveen Kumar
Journal:  J Clin Diagn Res       Date:  2015-11-01

9.  Effects of dihydropyridine calcium channel blockers on oxidized low-density lipoprotein induced proliferation and oxidative stress of vascular smooth muscle cells.

Authors:  Jun Zou; Yan Li; Hong-Qi Fan; Ji-Guang Wang
Journal:  BMC Res Notes       Date:  2012-07-06

10.  Phosphodiesterase-III Inhibitors Amrinone and Milrinone on Epilepsy and Cardiovascular Activities.

Authors:  Mohammad Asif
Journal:  N Am J Med Sci       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.